Cowen Starts Akcea Therapeutics, Inc. (AKCA) at Outperform
Tweet
Share
E-mailGet Alerts AKCA Hot Sheet
Price: $18.17 --0%
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Cowen initiates coverage on Akcea Therapeutics, Inc. (NASDAQ: AKCA) with a Outperform rating.
Analyst Eric Schmidt expects shares to outperform citing Volanesorsen commercialization and the advanced development of AKCEA-APO(a)-LRx, AKCEA-APOCIII-LRx, and AKCEA-ANGPTL3-LRx.
For an analyst ratings summary and ratings history on Akcea Therapeutics, Inc. click here. For more ratings news on Akcea Therapeutics, Inc. click here.
Shares of Akcea Therapeutics, Inc. closed at $14.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
- Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
- Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
